Recent Advancements in the Therapeutic Landscape of IgA Nephropathy and the Impact of Dual Blockers: Telitacicept - PubMed

an hour ago

IgA nephropathy (IgAN) has a variable and unpredictable course, often leading to significant patient morbidity and mortality.
Long-term corticosteroids and immunosuppressive therapy, the conventional treatments for IgAN, are limited by side effects that reduce adherence and efficacy.
There is a growing need for new, long-term treatments that avoid these side effects and prevent progression to end-stage renal disease.
Research is focusing on pathogenesis-specific treatments, highlighting the key role of the BAFF/APRIL axis in IgAN's development.
Telitacicept, a fully human IgG1-Fc soluble fusion protein, is reviewed as a promising drug targeting the BAFF/APRIL pathway to slow kidney damage in IgAN.

Hasty Briefsbeta